Another Phase III Failure For Lenvima Combo, But Lots More Room For Keytruda Growth
Head And Neck Cancer Disappointment
The combination of Keytruda plus Eisai’s Lenvima combination may be reaching the limit of its potential, but the US giant’s blockbuster PD-1 therapy has plenty more opportunities to maintain its growth for the next five years.
